We hosted an exclusive forum featuring top scientists and thought leaders in Substance Use Disorder (SUD) and mental health research. This event provided an opportunity to gain insights into cutting-edge advancements aimed at combating this devastating disease.

I. Welcome: Nancy Davis, Founder and President of CAN

II. Moderator and Introduction of Panel: Kurt Rasmussen, Ph.D., CSO Delix Therapeutics

III. Living with substance use disorder: Colby Betschart, Recovery Advocate

IV. Topics

1. Current Gaps in Care for Persons Using Substances: Kelly E. Dunn, Ph.D., Johns Hopkins University School of Medicine
2. Fresh out of the Pipeline - New FDA-Approved Treatments for Opioid Use Disorder and Overdose: Justin C. Strickland, Ph.D., Johns Hopkins University School of Medicine
3. Ozempic and other GLP-1 agonists as treatments for SUDs: Paul J. Kenny, Ph.D., Icahn School of Medicine at Mount Sinai
4. Psychedelics as Therapeutics: Kathryn A. Cunningham, Ph.D. University of Texas Medical Branch
5. Why Does Xylazine (Tranq) Matter in the Opioid Epidemic? Charles Chavkin, Ph.D., University of Washington
6. New Treatments to Promote Stress Resilience: Cassandra D. Gipson-Reichardt, Ph.D., University of Kentucky
7. The Complexity of Craving: Cecilia Bergeria, Ph.D., Johns Hopkins University School of Medicine
8. Public Health Policy and SUD: Adam Kaplin, M.D, Ph.D., CSO MyMD Pharmaceuticals
9. Discovering Targets and Treatments for Opioid Withdrawal Symptoms: Barbara Juarez, Ph.D., University of Maryland, Baltimore School of Medicine

IV. Lightning Round: Answers to Submitted Questions

V. Conclusion and Thank You by Nancy Davis